Serum Lysophosphatidic Acid as a Potential Biomarker of Prostate Cancer

Background: According to statistical data, prostate cancer is the most prevalent tumor inmenworldwide and is the second leading cause of cancer deaths among men in the United States. This cancer changes many factors in the blood of patients. Objectives: This study was designed to evaluate lysophosphatidic acid (LPA) levels in the serum of patients with prostate cancer. Methods: After collecting blood samples from 20 healthy individuals and 20 patients with prostate cancer, serum was separated from each sample. Then, the enzyme-linked immunosorbent assay (ELISA) method was applied to measure the serum LPA. The obtained data were statistical analyzed by SPSS V. 24 software. Results: The results of this study showed that the mean BMI of the prostate cancer group was significantly lower than the control group (respectively 22.560.53 and 24.490.62) (P = 0.023); in addition, the LPA level (nmol/mL) in the serum of the patients was significantly higher than healthy subjects (respectively 2.7140.054 and 2.4670.097) (P = 0.037). Conclusions: The results showed that the serum LPA levels increased in prostate cancer, suggesting that lysophosphatidic acid may be considered as a biomarker in this cancer and will take part in the adjustment of the prostate cancer cells functions as a paracrine/autocrine mediator. This will be involved in the initiation, progression, and metastasis of prostate cancer.